{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:45:17Z","timestamp":1790718317822,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7463213F"],"award-info":[{"award-number":["7463213F"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7457116F"],"award-info":[{"award-number":["7457116F"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7653418F"],"award-info":[{"award-number":["7653418F"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7463012F"],"award-info":[{"award-number":["7463012F"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["FA\/2014\/314"],"award-info":[{"award-number":["FA\/2014\/314"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interuniversity Attraction Poles Belgian Federal gouvernment P7\/30"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41388-018-0669-2","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T11:03:17Z","timestamp":1547636597000},"page":"3521-3534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["ADAM10 mediates malignant pleural mesothelioma invasiveness"],"prefix":"10.1038","volume":"38","author":[{"given":"Christelle","family":"S\u00e9pult","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Bellefroid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Rocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Duysinx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3079-7941","authenticated-orcid":false,"given":"Didier","family":"Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"669_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","volume":"9","author":"A Bononi","year":"2015","unstructured":"Bononi A, Napolitano A, Pass HI, Yang H, Carbone M. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med. 2015;9:633\u201354.","journal-title":"Expert Rev Respir Med"},{"key":"669_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2013.07.014","author":"K Donaldson","year":"2013","unstructured":"Donaldson K, Poland CA, Murphy FA, Macfarlane M, Chernova T, Schinwald A. Pulmonary toxicity of carbon nanotubes and asbestos\u2014similarities and differences. Adv Drug Deliv Rev. 2013. https:\/\/doi.org\/10.1016\/j.addr.2013.07.014 .","journal-title":"Adv Drug Deliv Rev"},{"key":"669_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1378\/chest.08-2665","volume":"136","author":"M Ray","year":"2009","unstructured":"Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888\u201396.","journal-title":"Chest"},{"key":"669_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"669_CR5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1021\/pr0500096","volume":"4","author":"C Andreini","year":"2005","unstructured":"Andreini C, Banci L, Bertini I, Elmi S, Rosato A. Comparative Analysis of the ADAM and ADAMTS Families. J Proteome Res. 2005;4:881\u20138.","journal-title":"J Proteome Res"},{"key":"669_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/bjc.2015.288","volume":"113","author":"M Mullooly","year":"2015","unstructured":"Mullooly M, Mcgowan PM, Kennedy SA, Madden SF, Crown J, Donovan NO, et al. ADAM10: a new player in breast cancer progression? Br J Cancer. 2015;113:945\u201351.","journal-title":"Br J Cancer"},{"key":"669_CR7","doi-asserted-by":"publisher","first-page":"9263","DOI":"10.1007\/s13277-014-2201-9","volume":"35","author":"L Fu","year":"2014","unstructured":"Fu L, Liu N, Han Y, Xie C. ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells. Tumor Biol. 2014;35:9263\u20138.","journal-title":"Tumor Biol"},{"key":"669_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3892\/mmr.2014.2652","volume":"11","author":"S Liu","year":"2015","unstructured":"Liu S, Zhang WEI, Liu KAI, Ji BAI, Wang G. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells. Mol Med Rep. 2015;11:597\u2013602.","journal-title":"Mol Med Rep"},{"key":"669_CR9","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3892\/or.2012.2003","volume":"28","author":"J Guo","year":"2012","unstructured":"Guo J, He L, Yuan P, Wang P, Lu Y, Tong F, et al. ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway. Oncol Rep. 2012;28:1709\u201318.","journal-title":"Oncol Rep"},{"key":"669_CR10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/cas.12800","volume":"106","author":"B You","year":"2015","unstructured":"You B, Shan Y, Shi S, Li X, You Y. Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma. Cancer Sci. 2015;106:1506\u201314.","journal-title":"Cancer Sci"},{"key":"669_CR11","doi-asserted-by":"publisher","first-page":"L325","DOI":"10.1152\/ajplung.00294.2014","volume":"308","author":"D Dreymueller","year":"2015","unstructured":"Dreymueller D, Uhlig S, Ludwig A. DAM-family metalloproteinases in lung inflammation: potential therapeutic targets. Am J Physiol Lung Cell Mol Physiol. 2015;308:L325\u201343.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"669_CR12","first-page":"4077","volume":"123","author":"J Pruessmeyer","year":"2014","unstructured":"Pruessmeyer J, Hess FM, Alert H, Groth E, Pasqualon T, Schwarz N, et al. Leukoc require ADAM10 but Not ADAM17 their Migr Inflamm Recruit into alveolar Space. 2014;123:4077\u201389.","journal-title":"Leukoc require ADAM10 but Not ADAM17 their Migr Inflamm Recruit into alveolar Space"},{"key":"669_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biochi.2007.08.008","volume":"90","author":"N Rocks","year":"2008","unstructured":"Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochim. 2008;90:369\u201379.","journal-title":"Biochim"},{"key":"669_CR14","doi-asserted-by":"publisher","first-page":"127.","DOI":"10.1186\/1465-9921-10-127","volume":"10","author":"G Paulissen","year":"2009","unstructured":"Paulissen G, Rocks N, Gueders MM, Crahay C, Quesada-Calvo F, Bekaert S, et al. Role of ADAM and ADAMTS metalloproteinases in airway diseases. Respir Res. 2009;10:127.","journal-title":"Respir Res"},{"key":"669_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/138920108783497613","volume":"9","author":"ML Moss","year":"2008","unstructured":"Moss ML, Stoeck A, Yan W, Dempsey PJ. ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol. 2008;9:2\u20138.","journal-title":"Curr Pharm Biotechnol"},{"key":"669_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1541-7786.MCR-10-0139","volume":"8","author":"M Yilmaz","year":"2010","unstructured":"Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8:629\u201343.","journal-title":"Mol Cancer Res"},{"key":"669_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10585-006-9029-7","volume":"23","author":"L Derycke","year":"2006","unstructured":"Derycke L, Morbidelli L, Ziche M, De Wever O, Bracke M, Van Aken E. Soluble N-cadherin fragment promotes angiogenesis. Clin Exp Metastas-. 2006;23:187\u2013201.","journal-title":"Clin Exp Metastas-"},{"key":"669_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/jnr.490360105","volume":"36","author":"NE Paradies","year":"1993","unstructured":"Paradies NE, Grunwald GB. Purification and characterization of NCAD90, a soluble endogenous form of N-cadherin, which is generated by proteolysis during retinal development and retains adhesive and neurite-promoting function. J Neurosci Res. 1993;36:33\u201345.","journal-title":"J Neurosci Res"},{"key":"669_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1046\/j.1471-4159.2001.00140.x","volume":"76","author":"MA Utton","year":"2001","unstructured":"Utton MA, Eickholt B, Howell FV, Wallis J, Doherty P. Soluble N-cadherin stimulates fibroblast growth factor receptor dependent neurite outgrowth and N-cadherin and the fibroblast growth factor receptor co-cluster in cells. J Neurochem. 2001;76:1421\u201330.","journal-title":"J Neurochem"},{"key":"669_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1083\/jcb.151.6.1193","volume":"151","author":"J Kim","year":"2000","unstructured":"Kim J, Islam S, Kim YJ, Prudoff RS, Sass KM, Wheelock MJ, et al. N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol. 2000;151:1193\u2013205.","journal-title":"J Cell Biol"},{"key":"669_CR21","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1523\/JNEUROSCI.5126-08.2009","volume":"29","author":"ZA Kohutek","year":"2009","unstructured":"Kohutek ZA, Charles G, Redpath GT, Hussaini IM. ADAM-10-ediated N-Cadherin cleavage is protein kinase C- \u2423 dependent and promotes glioblastoma cell migration. J Neurosci. 2009;29:4605\u201315.","journal-title":"J Neurosci"},{"key":"669_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/modpathol.3800534","volume":"19","author":"H Yaziji","year":"2006","unstructured":"Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, Mcintosh MW, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19:514\u201323.","journal-title":"Mod Pathol"},{"key":"669_CR23","doi-asserted-by":"publisher","first-page":"14.","DOI":"10.1186\/s12987-016-0038-x","volume":"13","author":"B Shackleton","year":"2016","unstructured":"Shackleton B, Crawford F, Bachmeier C. Inhibition of ADAM10 promotes the clearance of A\u03b2 across the BBB by reducing LRP1 ectodomain shedding. Fluids Barriers CNS. 2016;13:14.","journal-title":"Fluids Barriers CNS"},{"key":"669_CR24","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/emboj\/21.8.1948","volume":"21","author":"P Marambaud","year":"2002","unstructured":"Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, et al. A presenilin-1\/g-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 2002;21:1948\u201356.","journal-title":"EMBO J"},{"key":"669_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/sj.emboj.7600548","volume":"24","author":"K Reiss","year":"2005","unstructured":"Reiss K, Maretzky T, Ludwig A, Tousseyn T, Strooper B De, Hartmann D, et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and b-catenin nuclear signalling. EMBO J. 2005;24:742\u201352.","journal-title":"EMBO J"},{"key":"669_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1535-6108(02)00150-2","volume":"2","author":"K Suyama","year":"2002","unstructured":"Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell. 2002;2:301\u201314.","journal-title":"Cancer Cell"},{"key":"669_CR27","first-page":"182","volume":"3","author":"W Zhang","year":"2015","unstructured":"Zhang W, Wu X, Wu L, Zhang W, Zhao X. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med. 2015;3:182.","journal-title":"Ann Transl Med"},{"key":"669_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jadohealth.2017.05.003","volume":"61","author":"YH Huang","year":"2017","unstructured":"Huang YH, Chang PY, Wong KS, Chang CJ, Lai JY, Chen JC. An age-stratified longitudinal study of primary spontaneous pneumothorax. J Adolesc Health. 2017;61:527\u201332.","journal-title":"J Adolesc Health"},{"key":"669_CR29","first-page":"739","volume":"114","author":"J Schnell","year":"2017","unstructured":"Schnell J, Koryllos A, Lopez-Pastorini A, Lefering R, Stoelben E. Spontaneous pneumothorax. Dtsch Arztebl Int. 2017;114:739\u201344.","journal-title":"Dtsch Arztebl Int"},{"key":"669_CR30","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3233\/JAD-150737","volume":"50","author":"F Schuck","year":"2016","unstructured":"Schuck F, Wolf D, Fellgiebel A, Endres K. Increase of alpha-Secretase ADAM10 in platelets along cognitively healthy aging. J Alzheimers Dis. 2016;50:817\u201326.","journal-title":"J Alzheimers Dis"},{"key":"669_CR31","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1074\/jbc.M505625200","volume":"281","author":"A Kern","year":"2006","unstructured":"Kern A, Roempp B, Prager K, Walter J, Behl C. Downregulation of endogenous amyloid precursor protein processing due to cellular aging. J Biol Chem. 2006;281:2405\u201313.","journal-title":"J Biol Chem"},{"key":"669_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep22850","volume":"6","author":"R Mezzapelle","year":"2016","unstructured":"Mezzapelle R, Rrapaj E, Gatti E, Ceriotti C, Marchis F De, Preti A. et al. Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells. Sci Rep. 2016;6:1\u201312.","journal-title":"Sci Rep"},{"key":"669_CR33","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1182\/blood-2002-12-3775","volume":"102","author":"C Hundhausen","year":"2003","unstructured":"Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102:1186\u201395.","journal-title":"Blood"},{"key":"669_CR34","first-page":"1","volume":"39","author":"Y Sun","year":"2017","unstructured":"Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1\/FGFR4 signaling. Tumor Biol.2017;39:1\u201310.","journal-title":"Tumor Biol."},{"key":"669_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejcb.2016.05.002","volume":"95","author":"T Nguyen","year":"2016","unstructured":"Nguyen T, Mege RM. N-Cadherin and fibroblast growth factor receptors crosstalk in the control of developmental and cancer cell migrations. Eur J Cell Biol. 2016;95:415\u201326.","journal-title":"Eur J Cell Biol"},{"key":"669_CR36","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","volume":"8","author":"YK Chae","year":"2017","unstructured":"Chae YK, Ranganath K, Hammerman PS, Mohindra N, Kalyan A, Matsangou M, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8:16052\u201374.","journal-title":"Oncotarget"},{"key":"669_CR37","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18:1855\u201362.","journal-title":"Clin Cancer Res"},{"key":"669_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","volume":"24","author":"JM Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld J, Iorio F. et al.Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition.Clin Cancer Res. 2018;24:84\u201394.","journal-title":"Clin Cancer Res"},{"key":"669_CR39","doi-asserted-by":"publisher","first-page":"35712","DOI":"10.1074\/jbc.M703231200","volume":"282","author":"ML Moss","year":"2007","unstructured":"Moss ML, Bomar M, Liu Q, Sage H, Dempsey P, Lenhart PM, et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem. 2007;282:35712\u201321.","journal-title":"J Biol Chem"},{"key":"669_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0013-4","volume":"6","author":"F Madoux","year":"2016","unstructured":"Madoux F, Dreymuller D, Pettiloud J, Santos R, Ludwig A, Fields GB, et al. Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate. Sci Rep. 2016;6:1\u201317.","journal-title":"Sci Rep"},{"key":"669_CR41","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/09537104.2016.1203396","volume":"28","author":"D Dreymueller","year":"2017","unstructured":"Dreymueller D, Ludwig A. Considerations on inhibition approaches for proinflammatory functions of ADAM proteases. Platelets. 2017;28:354\u201361.","journal-title":"Platelets"},{"key":"669_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.brainresbull.2016.03.020","volume":"126","author":"B Vincent","year":"2016","unstructured":"Vincent B. Regulation of the \u03b1-secretase ADAM10 at transcriptional, translational and post-translational levels. Brain Res Bull. 2016;126:154\u201369.","journal-title":"Brain Res Bull"},{"key":"669_CR43","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, You H, Xiao G, Ramos-nino ME, Skele KL, Rienzo A De. et al.Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24:6080\u20139.","journal-title":"Oncogene"},{"key":"669_CR44","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","volume":"65","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, Vaslet CA, Skele KL, Rienzo A De, Devarajan K, Jhanwar SC. et al. Priority report a mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005;65:8090\u20136.","journal-title":"Cancer Res"},{"key":"669_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1078\/0344-0338-00427","volume":"199","author":"J Bot","year":"2003","unstructured":"Bot J, Whitaker D, Vivian J, Lake R, Yao V, Mccauley R. Animal and in vitro models in human diseases culturing mouse peritoneal mesothelial cells. Pathol Res Pr. 2003;199:341\u20134.","journal-title":"Pathol Res Pr"},{"key":"669_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1179064417738513","volume":"10","author":"K Donati","year":"2017","unstructured":"Donati K, S\u00e9pult C, Rocks N, Blacher S, G\u00e9rard C, Noel A, et al. Neutrophil-derived interleukin 16 in premetastatic lungs promotes breast tumor cell seeding. Cancer Growth Metastas-. 2017;10:1\u201314.","journal-title":"Cancer Growth Metastas-"},{"key":"669_CR47","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/sj.bjc.6602990","volume":"94","author":"N Rocks","year":"2006","unstructured":"Rocks N, Paulissen G, Quesada Calvo F, Polette M, Gueders M, Munaut C, et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer. 2006;94:724\u201330.","journal-title":"Br J Cancer"},{"key":"669_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062818","volume":"8","author":"E Otjacques","year":"2013","unstructured":"Otjacques E, Binsfeld M, Rocks N, Blacher S, Vanderkerken K, Noel A, et al. Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors. PLoS ONE. 2013;8:e62818.","journal-title":"PLoS ONE"},{"key":"669_CR49","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.neo.2015.07.002","volume":"17","author":"O Carnet","year":"2015","unstructured":"Carnet O, Lecomte J, Masset A, Primac I, Durr\u00e9 T, Maertens L, et al. Mesenchymal stem cells shed amphiregulin at the surface of lung carcinoma cells in a juxtacrine. NEO. 2015;17:552\u201363.","journal-title":"NEO"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0669-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:15:05Z","timestamp":1684617305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0669-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":49,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0669-2","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"12 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DC is the founder of Aquilon Pharmaceuticals, received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Mundipharma, Chiesi and GSK and received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Novartis for the participation to advisory boards. None of these activities are related to the therapy of cancer or mesothelioma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The experimental protocols for animal studies were examined and approved on 6 May 2011 and 26 May 2016 by Ethical Committee (University of Liege) and accepted under the reference numbers #1201 and #1757. The study protocol for human samples was approved by the Ethical Committee of University hospital of Li\u00e8ge (CHU) on 9 October 2012 and accepted under the reference number #B707201215113.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}